Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
CNOOC
00883
5
SINOPEC CORP
00386
CA Stock MarketDetailed Quotes
NurExone Biologic Inc (NRX)
- 0.540
- -0.010-1.82%
15min DelayMarket Closed May 6 13:53 ET
49.70MMarket Cap-4.91P/E (TTM)
0.560High0.540Low15.10KVolume0.550Open0.550Prev Close8.35KTurnover1.14052wk High0.02%Turnover Ratio92.05MShares0.54052wk Low-0.11EPS TTM47.18MFloat Cap1.190Historical HighLossP/E (Static)87.37MShs Float0.100Historical Low-0.11EPS LYR3.64%Range %--Dividend TTM13.17P/B1Lot Size--Div Yield TTM
NurExone Biologic Inc (NRX) Income Statement
Quarterly+Annual
YOY
| (FY)Dec 31, 2025 | (Q4)Dec 31, 2025 | (Q3)Sep 30, 2025 | (Q2)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating revenue | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 |
| Cost of revenue | ||||||||||
| Gross profit | ||||||||||
| Operating expense | 26.23%6.32M | -10.04%1.34M | 14.09%1.47M | 38.03%1.82M | 84.78%1.7M | 36.97%5.01M | 107.26%1.48M | 10.40%1.29M | 24.53%1.32M | 27.96%920K |
| Selling and administrative expenses | 17.42%3.65M | -16.91%683K | -2.43%763K | 38.55%1.13M | 55.68%1.08M | 48.50%3.11M | 112.95%822K | 2.62%782K | 34.66%812K | 101.45%695K |
| -General and administrative expense | 17.42%3.65M | -16.91%683K | -2.43%763K | 38.55%1.13M | 55.68%1.08M | 48.50%3.11M | 112.95%822K | 2.62%782K | 34.66%812K | 101.45%695K |
| Research and development costs | 41.17%2.64M | -2.06%619K | 39.76%703K | 37.20%697K | 174.67%618K | 21.22%1.87M | 104.53%632K | 25.12%503K | 11.16%508K | -39.84%225K |
| Depreciation amortization depletion | 10.00%33K | ---- | ---- | ---- | ---- | 42.86%30K | ---- | ---- | ---- | ---- |
| -Depreciation and amortization | 10.00%33K | ---- | ---- | ---- | ---- | 42.86%30K | ---- | ---- | ---- | ---- |
| Operating profit | -26.23%-6.32M | 10.04%-1.34M | -14.09%-1.47M | -38.03%-1.82M | -84.78%-1.7M | -36.97%-5.01M | -107.26%-1.48M | -10.40%-1.29M | -24.53%-1.32M | -27.96%-920K |
| Net non-operating interest income (expenses) | -156.67%-17K | -900.00%-16K | -97.14%1K | -380.00%-24K | 1,200.00%22K | -28.57%30K | -33.33%2K | 483.33%35K | -125.00%-5K | -114.29%-2K |
| Non-operating interest income | -70.21%14K | -1,175.00%-43K | -43.24%21K | -43.75%9K | 450.00%33K | --47K | --4K | 516.67%37K | -38.46%16K | --6K |
| Non-operating interest expense | 82.35%31K | -1,450.00%-27K | 900.00%20K | 57.14%33K | 37.50%11K | 466.67%17K | 166.67%2K | --2K | 250.00%21K | --8K |
| Total other finance cost | ---- | ---- | ---- | ---- | ---- | -4.44%-47K | ---- | ---- | ---- | 114.29%2K |
| Other net income (expenses) | 32.31%-44K | -170.83%-65K | ||||||||
| Gain on sale of security | -113.04%-49K | ---- | ---- | ---- | ---- | -1,050.00%-23K | ---- | ---- | ---- | ---- |
| Other non-operating income (expenses) | 111.90%5K | ---- | ---- | ---- | ---- | -90.91%-42K | ---- | ---- | ---- | ---- |
| Income before tax | -26.57%-6.38M | 9.83%-1.4M | -17.20%-1.47M | -39.32%-1.85M | -82.00%-1.68M | -38.61%-5.04M | -109.91%-1.55M | -7.94%-1.25M | -27.40%-1.33M | -30.78%-922K |
| Income tax | ||||||||||
| Earnings from equity interest net of tax | ||||||||||
| Net income | -26.57%-6.38M | 9.83%-1.4M | -17.20%-1.47M | -39.32%-1.85M | -82.00%-1.68M | -38.61%-5.04M | -109.91%-1.55M | -7.94%-1.25M | -27.40%-1.33M | -30.78%-922K |
| Net income continuous operations | -26.57%-6.38M | 9.83%-1.4M | -17.20%-1.47M | -39.32%-1.85M | -82.00%-1.68M | -38.61%-5.04M | -109.91%-1.55M | -7.94%-1.25M | -27.40%-1.33M | -30.78%-922K |
| Noncontrolling interests | ||||||||||
| Net income attributable to the company | -26.59%-6.38M | 9.77%-1.4M | -17.20%-1.47M | -39.32%-1.85M | -82.00%-1.68M | -38.58%-5.04M | -109.77%-1.55M | -7.94%-1.25M | -27.40%-1.33M | -30.78%-922K |
| Preferred stock dividends | ||||||||||
| Other under preferred stock dividend | ||||||||||
| Net income attributable to common stockholders | -26.59%-6.38M | 9.77%-1.4M | -17.20%-1.47M | -39.32%-1.85M | -82.00%-1.68M | -38.58%-5.04M | -109.77%-1.55M | -7.94%-1.25M | -27.40%-1.33M | -30.78%-922K |
| Diluted earnings per share | 0.00%-0.08 | 0.00%-0.02 | 0.00%-0.02 | -9.09%-0.024 | -43.75%-0.023 | 1.23%-0.08 | -33.33%-0.02 | 23.08%-0.02 | 8.33%-0.022 | 0.00%-0.016 |
| Basic earnings per share | 0.00%-0.08 | 0.00%-0.02 | 0.00%-0.02 | -9.09%-0.024 | -43.75%-0.023 | 1.23%-0.08 | -33.33%-0.02 | 23.08%-0.02 | 8.33%-0.022 | 0.00%-0.016 |
| Dividend per share | ||||||||||
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
Market Insights
Hot Topics Hot Topics
Middle East conflict spreads to the stock market! How should investors respond?
The negotiations between the US and Iran have entered a critical window amid external expectations and various parties' maneuvering, with th
牛牛課堂
Mar 4 17:09
Long-term answers | Your account on the left shrinks, while your right hand is chased by the times — Be the person that no bombardment can ever wipe out.
牛牛課堂
Mar 18 18:18
Hormuz, Term Structure and USO: Navigating the Energy Storm